Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis

NCT03138733 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT03138733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03138733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 3
Overall status
Completed
Start date
August 26, 2018
Completion date
March 11, 2022
Enrollment
390 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus bacteremia